TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04007289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
Study: NCT02996799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: Milking of the umbilical cord at delivery
Study: NCT00545740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD orally
Study: NCT00641979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Current product
Study: NCT00600769

Intervention type: DRUG
Group type: OTHER
Intervention: Clarithromycin
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Study: NCT00633789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivanib
Description: Tablets, Oral, 800 mg, once daily, until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, until progression
Study: NCT03857321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (sterile saline) to 20 IU Humulin® R U-100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (sterile saline) to 20 IU Humulin® R U-100
Study: NCT00532792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
Study: NCT03378648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6366
Description: Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CHF6366
Description: Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: umeclidinium bromide and vilanterol trifenatate
Description: Part 3 Single dose
Study: NCT01066780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearVoice
Description: ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearVoice
Description: ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
Study: NCT04304183

Intervention type: PROCEDURE
Intervention: total colectomy, ileorectal anastomosis
Description: all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
Study: NCT00641979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: New type device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04316741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snapcoach
Description: A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
Study: NCT00152568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Car Seat Check (behavior)
Description: At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
Study: NCT01048294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Original Energy Light,
Description: 9000 lux, 30 minutes in the morning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Original Energy Light prototype
Description: 9000 lux 20 minutes in the morning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Original Energy Light prototype
Description: 9000 lux 30 minutes in the morning
Study: NCT05709587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Description: Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
Study: NCT06100367

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
Description: 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
Study: NCT01269385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT03857321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intranasal nebulizer-like device
Description: Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intranasal nebulizer-like device
Description: Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
Study: NCT03538899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AProArt-CD34
Description: Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® CD34 Reagent System cell sorter device
Description: Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
Study: NCT04490499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBVAXPRO™
Description: Single 0.5 mL intramuscular dose
Study: NCT04139421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shinrin-Yoku
Description: Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shinrin-Yoku
Description: Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
Study: NCT00329992

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Eclectic Psychotherapy for PTSD
Description: 16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Eclectic Psychotherapy for PTSD
Description: 16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
Study: NCT02826083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XXS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: non-XXS
Study: NCT03839576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized training
Description: Attention, memory, speed of processing, and executive functioning.
Study: NCT01326481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral
Study: NCT01038635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: 75 mg/m\^2 IV daily x 5 days on days 1 to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose 10 mg orally daily x 5 days on days 6 to 10.
Study: NCT04754867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Self Virtual Reality Image - Normal Aging
Description: Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Self Virtual Reality Image - Normal Aging
Description: Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Self Virtual Reality Image - Smoking Consequences Aging
Description: Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Current Self Virtual Reality Image
Description: Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter - 20 years
Description: Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter - 20 years
Description: Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter - 3 months
Description: Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?
Study: NCT03202667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg
Description: Treatment with empagliflozin 25mg once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo oral tablet once daily for 28 days
Study: NCT02605889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: Laser acupuncture
Study: NCT01306240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surfactant instillation
Description: Intra-tracheal poractant alpha instillation after tracheal intubation
Study: NCT01351259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic device, cylindrical or tapered cuff
Description: Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
Study: NCT01269385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGG beta-glucan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03143569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aPTT guided heparin management
Description: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aPTT guided heparin management
Description: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-factor Xa guided heparin management
Description: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
Study: NCT01351259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic device, cylindrical or tapered cuff
Description: Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic device, cylindrical or tapered cuff
Description: Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic device, cylindrical or tapered cuff
Description: Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
Study: NCT02309294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel lubricant Miami w/ fragrance
Description: 0.2 ml aliquot on occlusive patch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel lubricant Miami no fragrance
Description: 0.2 ml aliquot on occlusive patch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KY Liquid lubricant
Description: 0.2 ml aliquot on occlusive patch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astroglide Gel lubricant
Description: 0.2 ml aliquot on occlusive patch
Study: NCT03143569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-factor Xa guided heparin management
Description: post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
Study: NCT00494832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour
Study: NCT00744627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study: NCT04826146

Intervention type: DEVICE
Intervention: Validation of qCON versus BIS
Description: Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
Study: NCT01254526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral repeating dose
Study: NCT02309294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wet Platinum lubricant
Description: 0.2 ml aliquot on occlusive patch
Study: NCT02372318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18mg of Nalmefen will be administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01254526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study: NCT02448654

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone
Description: Tolcapone will be compared to sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: The sugar pill (placebo) will be compared to tolcapone
Study: NCT02677922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Specified dose on specified days
Study: NCT01326767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel dosing according to SmPC
Description: Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized pharmacokinetically driven paclitaxel dosing
Description: Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
Study: NCT01166178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg once a year via intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to zoledronic acid once a year via intravenous infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D combination
Description: Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D combination
Description: Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
Study: NCT03375424

Intervention type: BIOLOGICAL
Intervention: vedolizumab
Description: duration of disease and kind of therapy
Study: NCT04153851

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neurectomy of nasopalatine nerve
Description: Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
Study: NCT00446368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
Study: NCT00358566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV1001
Description: 0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine (Chemotherapy)
Description: Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
Study: NCT02400502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CAT Therapy
Description: I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
Study: NCT01269385

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study: NCT02441569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common factors engagement training for provider
Description: Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
Study: NCT01306240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
Study: NCT00952133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palonosetron only
Description: The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron with Dexamethasone
Description: Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.